Core Viewpoint - Zhifei Biological's subsidiary, Zhifei Longkema, has received the clinical trial application acceptance notice from the National Medical Products Administration for its recombinant varicella-zoster virus vaccine ZFA01 adjuvanted with CHO cells [1] Group 1 - The vaccine ZFA01 is designed to target shingles, a disease caused by the varicella-zoster virus [1] - The acceptance of the clinical trial application marks a significant step in the development of this vaccine [1]

智飞生物（300122）(300122.SZ)公告，公司全资子公司安徽智飞龙科马生物制药有限公司(简称"智飞龙 科马")研发的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验申请受理 通知书。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按照提交的方案开 展临床试验。 ...

Core Viewpoint - The company Zhifei Biological Products Co., Ltd. has received a clinical trial application acceptance notice from the National Medical Products Administration for its recombinant herpes zoster vaccine ZFA01, developed by its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. [1] Group 1 - The clinical trial application for the ZFA01 adjuvanted vaccine has been accepted, allowing the company to proceed with clinical trials if no negative or questioning opinions are received within 60 days from the acceptance date [1]

证券代码：300122 证券简称：智飞生物 公告编号：2025-70 重庆智飞生物制品股份有限公司 关于重组带状疱疹 ZFA01 佐剂疫苗（CHO 细胞） 带状疱疹（herpes zoster）是由长期潜伏在脊髓后根神经节或颅神经节内的 水痘-带状疱疹病毒（varicella-zoster virus，VZV）经再激活引起的感染性皮肤病。 有数据表明，90%以上的成人体内都潜伏有水痘-带状疱疹病毒，大约 1/3 的人在 一生中会患带状疱疹。带状疱疹是皮肤科常见病，除皮肤损害外，常伴有神经病 理性疼痛，多见于年龄较大、免疫抑制或免疫缺陷等人群，严重影响患者生活质 量。带状疱疹后神经痛（PHN）为带状疱疹最常见的并发症，其发生率为 5%-30%， 多见于高龄、免疫功能低下患者。该并发症疼痛部位通常比疱疹区域有所扩大， 常见于单侧肋间神经、三叉神经（主要是眼支）或颈神经。疼痛性质多样，可为 烧灼样、电击样、刀割样、针刺样或撕裂样。30%-50%的患者疼痛持续超过 1 年，部分病程可达 10 年或更长。接种疫苗是最有效可行的预防带状疱疹及带状 疱疹后神经痛的手段。智飞龙科马研发的重组带状疱疹 ZFA01 佐剂疫苗（C ...

证券代码：300122 证券简称：智飞生物 公告编号：2025-69 2.本次股东会未涉及变更前次股东会决议。 一、会议召开和出席情况 1、会议召开情况 （1） 时间： 现场会议：2025年11月18日（星期二）9:00； 网络投票：2025年11月18日。其中，通过深圳证券交易所交易系统进行网络投 票的时间为2025年11月18日上午9:15-9:25、9:30-11:30，下午13:00-15:00；通过深圳 证券交易所互联网系统投票的具体时间为：2025年11月18日9:15-15:00； 重庆智飞生物制品股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示 1.本次股东会未出现否决议案的情形； （2） 现场会议地点：重庆市江北区金源路9号重庆君豪大饭店； （3） 会议方式：本次会议以现场投票与网络投票相结合的方式召开； （6） 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》《中华人 民共和国证券法》《上市公司股东会规则》等有关法律、行政法规、部门规章、规范 性文件及《重庆智飞生物制品股 ...

北京市金杜（重庆）律师事务所 关于重庆智飞生物制品股份有限公司 2025 年第二次临时股东会的法律意见书 致：重庆智飞生物制品股份有限公司 北京市金杜（重庆）律师事务所（以下简称"本所"）接受重庆智飞生物制 品股份有限公司（以下简称"公司"）的委托，根据《中华人民共和国证券法》 （以下简称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、 中国证券监督管理委员会《上市公司股东会规则》（以下简称"《股东会规则》"） 等中华人民共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中 国香港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政 法规、规章、规范性文件和现行有效的公司章程有关规定，指派律师出席了公司 于 2025 年 11 月 18 日召开的 2025 年第二次临时股东会（以下简称"本次股东 会"），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了以下文件，包括但不限于： 1．经公司 2024 年 6 月 18 日召开的 2023 年年度股东大会审议通过的《重 庆智飞生物制品股份有限公司章程》（以下简称"《公司章程》"）； 6．出席现场会议的股 ...

Core Viewpoint - The financial performance of Zhifei Biological is declining, with significant decreases in revenue and net profit, while the stock's financing and margin trading activities indicate a low level of investor confidence [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Zhifei Biological reported a revenue of 7.627 billion yuan, a year-on-year decrease of 66.53% [2]. - The company experienced a net profit attributable to shareholders of -1.206 billion yuan, representing a year-on-year decrease of 156.10% [2]. - Cumulatively, since its A-share listing, Zhifei Biological has distributed a total of 7.318 billion yuan in dividends, with 3.194 billion yuan distributed over the past three years [2]. Group 2: Stock and Financing Activity - On November 17, Zhifei Biological's stock price fell by 1.30%, with a trading volume of 493 million yuan [1]. - The financing buy-in amount for Zhifei Biological on the same day was 50.144 million yuan, while the financing repayment was 55.099 million yuan, resulting in a net financing buy-in of -4.9549 million yuan [1]. - The total margin trading balance for Zhifei Biological as of November 17 was 1.406 billion yuan, with the financing balance accounting for 2.76% of the circulating market value, which is below the 30% percentile level over the past year [1]. Group 3: Shareholder Structure - As of November 10, the number of shareholders for Zhifei Biological was 133,100, an increase of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder was 10,624 shares, a decrease of 1.17% from the previous period [2]. - Major institutional shareholders have reduced their holdings, with significant decreases noted among the top ten circulating shareholders [2].

Group 1 - The restructuring protein concept declined by 1.71%, ranking among the top declines in the concept sector, with notable declines in stocks such as Kexing Pharmaceutical, Haoyuan Pharmaceutical, and Zejing Pharmaceutical [1] - Among the stocks in the restructuring protein concept, 8 stocks saw price increases, with *ST Wanfang, ST Weiming, and Lideman leading with increases of 4.96%, 2.21%, and 1.76% respectively [1] - The restructuring protein concept experienced a net outflow of 742 million yuan from main funds today, with 38 stocks seeing net outflows, and 8 stocks with outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock in the restructuring protein concept was Heyuan Biological, with a net outflow of 82.99 million yuan, followed by Sangfor Guojian, Zhifei Biological, and Zhongyuan Xiehe with net outflows of 59.97 million yuan, 57.83 million yuan, and 56.32 million yuan respectively [2][3] - The stocks with the highest net inflow included *ST Wanfang, Furuida, and Yinuote, with net inflows of 10.67 million yuan, 8.92 million yuan, and 7.75 million yuan respectively [4]

证券日报网讯智飞生物（300122）11月14日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司普通股股东人数为133，119户。 ...

Group 1 - The core point of the article is the approval of a new drug, Pugilone Injection, by Chongqing Precision Biotechnology, which is expected to have a significant impact on the company and its investors [2] - Zhifei Biological, a company listed on the Shenzhen Stock Exchange, has a stake in Chongqing Zhihui Investment Co., which incubated Chongqing Precision Biotechnology [2] - The new drug is classified as a national Class 1 biological new drug, indicating its importance and potential in the market [2]